# Iberdomide

Source: https://onco.cc/drugs/iberdomide/  
OnCo record `iberdomide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease.

## Summary

Iberdomide is a cereblon E3 ligase modulator (CELMoD) that binds cereblon with around 20-fold higher affinity than lenalidomide, degrading Ikaros and Aiolos more completely and so killing myeloma cells and stimulating T cells more potently. Because it acts through the same pathway with greater force, it is active in lenalidomide-refractory disease: in CC-220-MM-001 the doublet with dexamethasone gave an ORR of about 26%, higher in combinations. Its main development is as post-transplant maintenance, where the phase 3 EXCALIBER-Maintenance trial against lenalidomide met its primary endpoint according to BMS reports in 2026, and in relapsed disease, where EXCALIBER-RRMM (Iber-Dd versus Dara-Vd) is ongoing. It is a more powerful successor to lenalidomide aiming to keep myeloma in remission longer after transplant.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Zenbexus
- Code: CC-220
- Modality: CELMoD (cereblon E3 ligase modulator)
- Mechanism: Binds cereblon with ~20-fold higher affinity than lenalidomide, degrading Ikaros/Aiolos more completely.
- Approvals: US 2026: Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effective 13 August 2026)

## Sources

- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Iberdomide

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Cereblon E3 ligase modulators (CELMoDs)](https://onco.cc/technologies/celmods/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma](https://onco.cc/trials/nct05583617/), [A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe](https://onco.cc/trials/nct06892522/), [A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly](https://onco.cc/trials/nct05827016/), [A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple](https://onco.cc/trials/nct02773030/), [Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ](https://onco.cc/trials/nct04975997/)
- pathways: [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)

---
JSON: https://onco.cc/api/v1/entities/iberdomide.json